Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01941628
Other study ID # RocSuc
Secondary ID 2013-003077-97
Status Completed
Phase Phase 4
First received
Last updated
Start date August 16, 2014
Est. completion date April 3, 2018

Study information

Verified date February 2019
Source Charles University, Czech Republic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cesarean delivery under general anesthesia is one of few only surgical procedures, where the most important factor of safety is the speed of the surgery, as a newborn adaptation strongly depends on a time between induction to the general anesthesia (and administration of anesthetics) and pennywort ligation. The shortest possible interval is essential for the amount of anesthetics crossing placenta into the fetal circulation.

The primary objective:

To compare surgical conditions for fetus delivery in Cesarean section under general anesthesia with deep neuromuscular blockade versus standard procedure with succinylcholine.

The primary safety objective:

To compare influence of different levels of neuromuscular blockade and surgical conditions on newborn adaptation after the Cesarean delivery.

The secondary objectives:

To compare influence of deep versus no/shallow muscle blockade during the entire Cesarean section on surgical conditions for suture of the uterus and the abdominal wall with attention to blood loss, time of surgery and surgical complications.

To describe pharmacodynamics and pharmacokinetics of deep neuromuscular blockade by rocuronium over the course of Cesarean section and its reversal by sugammadex at the end of procedure.

Clinical hypotheses:

The use of deep muscle blockade in Cesarean section under general anesthesia, including the period of fetus delivery, compare to the standard recommended practice with succinylcholine, will improve the surgical conditions and allow faster and easier delivery of the fetus with positive effect on its postnatal adaptation. Faster delivery will reduce an incision to delivery interval with decrease of time between anesthetics administration and delivery. This will reduce the amount of anesthetics crossing the placenta to the fetal circulation. Both, reduced amount of anesthetics and reduced incision to delivery interval itself will improve a newborn adaptation after Cesarean delivery.

Deep neuromuscular blockade will also improve surgical conditions for the whole surgery, when no or shallow only neuromuscular blockade is routinely used. We assume that deep neuromuscular blockade during the entire surgery will create better surgical conditions for faster and easier uterus suture and the rest of surgery and thus reduce perioperative blood loss and incidence of surgical complications.


Description:

Cesarean delivery under general anesthesia is one of few only surgical procedures, where the most important factor of safety is the speed of the surgery, as a newborn adaptation strongly depends on a time between induction to the general anesthesia (and administration of anesthetics) and pennywort ligation. The shortest possible interval is essential for the amount of anesthetics crossing placenta into the fetal circulation.

The same requirement for the fastest time applies for the suture of uterus, when the duration of suture directly affects an amount of blood loss. Hence creating the best surgical conditions allowing the fastest delivery and performance of whole surgery, safe for the fetus and the mother, should be an extremely important. The question is, whether recent recommendations for Cesarean section under general anesthesia best meet these requirements. We assume that by creating better surgical conditions it could be positively affected not only the time and safety of fetus delivery (and thus its adaptation), but also the reduction of perioperative blood loss and the incidence of surgical complications (primarily subfascial hematoma, bladder injury, dehiscence, surgical site infection).

For higher risk of regurgitation and aspiration rapid sequence induction into the general anesthesia is the method of choice for Cesarean section for more than last forty years [1]. This means that intubation in apnoeic pause should be performed as soon as possible after administration of anesthetics and muscle relaxant. The traditional basic requirements on the administered muscle relaxant then primarily are a time of onset of its action and a creation of good intubating conditions. The depolarizing agent succinylcholine (1 to 1.5 mg/kg) is still worldwide recommended the muscle relaxant of choice for most parturients undergoing rapid-sequence induction for general anesthesia as provides adequate intubating conditions within approximately 45 seconds of intravenous administration [2]. But essential likewise is, that administration of muscle relaxant does not affect only the creation of intubating conditions, but the effect on relaxation of the abdominal wall muscles has an effect also on surgical conditions for fetus delivery. Surprisingly, and to our knowledge, this effect has not been studied yet. From this perspective, and taking into account the negative effects of succinylcholine, rocuronium seems to be preferable alternative. Rocuronium in the dose of 0.6 mg/kg in pregnant women induces good intubating conditions similar to succinylcholine [1, 3, 4], in a still reasonable time for apnoeic intubation [5]. But compare to succinylcholine, which allows only very short muscle blockade (and may thus prolong a delivery in complicated cases with all the consequences on postnatal fetus adaptation), rocuronium induces deep muscle relaxation and so should offer better surgical conditions for easier and faster fetus delivery.

As stated in recent recommendations, additional neuromuscular blockade after fetus delivery is either not necessary (provided that the mother has an adequate depth of anesthesia with administration of both a volatile agent and an opioid), or a small dose of a short-acting nondepolarizing agent (or an infusion of succinylcholine) can be administered [2]. This means, if succinylcholine is used as a muscle relaxant, due to its very short action the surgery is performed in no or shallow only neuromuscular blockade. We again assume that deep neuromuscular blockade during the surgery will offer better surgical conditions for suture of the uterus and the rest of surgery and thus reduce time of the surgery and perioperative blood loss and even incidence of surgical complications. Such comparison has not been studied to date.

Comparison of surgical conditions for fetus delivery and its influence on fetus adaptation has not been also investigated yet. Unanswered question then is, whether deep muscle blockade wit rocuronium, allowing improved surgical conditions can also improve newborn adaptation compare to traditional approach with succinylcholine.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date April 3, 2018
Est. primary completion date December 30, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- pregnant women undergoing Cesarean section under general anesthesia

- at least 18 years of age

- results of a physical and laboratory preoperative examination within normal limits or clinically acceptable limits for the study

- written informed consent

Exclusion Criteria:

- urgent Cesarean section

- multiple pregnancy

- abnormal placentation

- prematurity (<34 weeks)

- severe fetal hypoxia

- history of severe pre-existing disease

- hypersensitivity or allergy to rocuronium or sugammadex

Discontinuation Criteria:

- a subject's choice to end participation in the study

- a subject meets any exclusion criteria during the study or equivalent criteria

- lost to follow up

- the investigator feels that it's in the subject's best interest to discontinue the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rocuronium
Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
Succinylcholine
Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.

Locations

Country Name City State
Czechia General University Hospital in Prague Prague

Sponsors (2)

Lead Sponsor Collaborator
Charles University, Czech Republic General University Hospital, Prague

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Induction to Delivery Interval Induction to delivery interval will be used as primary keypoint for surgical conditions comparison. 24 hrs
Primary Number of Participants With Newborn in Need of Respiratory Support The number of participants with a newborn in need of respiratory support will be the primary safety measure in comparison of the influence of different neuromuscular blockade levels on newborn adaptation. 24 hours
Secondary Peroperative and Postoperative Surgical Complication A total number of surgical complications evaluated at day 5 after Caesarean delivery. 5 days
See also
  Status Clinical Trial Phase
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03631329 - Predictability of Preoperative Carotid Artery Corrected Flow Time for Hypotension After Spinal Anesthesia in Patients Undergoing Cesarean Section
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Active, not recruiting NCT03760718 - Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery Early Phase 1
Active, not recruiting NCT04965779 - The Effect of Abdominal Binder Use on Postpartum Pain, Bleeding, and Breastfeeding Success in Cesarean Delivery Women N/A
Terminated NCT01687972 - INSORB Versus Subcuticular Sutures at Cesarean Section Phase 1
Withdrawn NCT01211431 - Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine Phase 4
Completed NCT00987701 - Perineuraxial Anesthesia Fluid Management and Infant Neurobehaviors N/A
Completed NCT00991627 - Different Approaches to Maternal Hypotension During Cesarean Section Phase 4
Completed NCT01049477 - The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery N/A
Terminated NCT00524511 - Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples N/A
Completed NCT00375986 - A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section N/A
Terminated NCT00386477 - Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial N/A
Completed NCT00517140 - Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function N/A
Terminated NCT05051150 - Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Caesarean Section Phase 4
Terminated NCT03695172 - Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section Phase 4
Recruiting NCT06247852 - Persistent Pain After Cesarean Delivery - A Danish Multicenter Cohort Study
Completed NCT06012747 - Pain After Cesarean Section - A Danish Multicenter Cohort Study.
Not yet recruiting NCT05187520 - Naldebain for Control of Post-Cesarean Section Pain Phase 2
Not yet recruiting NCT04999670 - Fascial Closure and Post-caesarean Pain N/A